Dyadic International updates on its Alternative Proteins business and plans for vaccine and diagnostic advancements amid increased industry interest.
Quiver AI Summary
Dyadic International, Inc., a biotechnology firm specializing in large-scale protein production for vaccines and therapeutics, provided an update on its business development efforts, particularly in its Alternative Proteins sector and the application of its C1 platform for diagnostics and vaccines targeting infectious diseases like the H5N1 Avian Influenza. The company will attend the J.P. Morgan Healthcare Conference from January 13-16, 2025. CEO Mark Emalfarb highlighted the successful production of alternative proteins, which is generating significant revenue, along with renewed interest in C1 applications for human and animal health. This includes a $3 million grant from the Gates Foundation for RSV and Malaria initiatives, and partnerships focused on developing vaccines for monkeypox and avian influenza. Dyadic is also making progress on launching several non-animal dairy proteins and recombinant products, with product launches anticipated in 2025.
Potential Positives
- Dyadic has secured a $3 million grant from the Bill & Melinda Gates Foundation to focus on research related to RSV and Malaria, enhancing its credibility and financial backing.
- There is renewed industry interest in Dyadic’s C1 platform for human and animal health, indicating potential growth and expansion of its market applications.
- The company is preparing for key product launches in its Alternative Proteins business, which is expected to provide significant revenue opportunities in the near term.
- Dyadic’s attendance at the prestigious J.P. Morgan Healthcare Conference could facilitate valuable networking and partnership opportunities in the biotechnology sector.
Potential Negatives
- The press release emphasizes a reliance on grants and partnerships, which may indicate a lack of self-sustaining revenue from internal product offerings beyond alternative proteins.
- Forward-looking statements carry inherent risks, suggesting that actual results may significantly differ from expectations, potentially impacting investor confidence.
- The mention of significant ongoing collaborations with various partners raises questions about Dyadic's ability to independently manage its product development and market strategy.
FAQ
What is Dyadic International focused on?
Dyadic International specializes in the large-scale manufacture of proteins for vaccines, therapeutics, and various non-pharmaceutical applications.
What recent grant did Dyadic receive?
Dyadic received a $3 million grant from the Bill & Melinda Gates Foundation for research on RSV and malaria.
When will Dyadic present at the J.P. Morgan Healthcare Conference?
Dyadic management will attend the J.P. Morgan Healthcare Conference from January 13 to 16, 2025, in San Francisco.
What are the key platforms used by Dyadic?
Dyadic utilizes the C1 and Dapibus™ protein production platforms for developing proteins and related products.
What infectious diseases is Dyadic addressing with its C1 platform?
Dyadic's C1 platform aims to develop solutions for infectious diseases including H5N1 Avian Influenza and monkeypox.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DYAI Hedge Fund Activity
We have seen 12 institutional investors add shares of $DYAI stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 51,697 shares (+146.5%) to their portfolio in Q3 2024
- LPL FINANCIAL LLC added 33,038 shares (+222.5%) to their portfolio in Q3 2024
- CHAPIN DAVIS, INC. added 21,000 shares (+2.5%) to their portfolio in Q3 2024
- ROBERTSON STEPHENS WEALTH MANAGEMENT, LLC removed 20,000 shares (-40.0%) from their portfolio in Q3 2024
- WOLVERINE TRADING, LLC removed 13,647 shares (-100.0%) from their portfolio in Q3 2024
- XTX TOPCO LTD added 13,252 shares (+inf%) to their portfolio in Q3 2024
- MORGAN STANLEY added 11,800 shares (+2599.1%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
JUPITER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, provided an update on its business development efforts related to its Alternative Proteins business and emerging interest in leveraging the C1 platform in the diagnostic and vaccine space to address a variety of infectious diseases, such as the H5N1 Avian Influenza (“Bird Flu”) outbreak. The Company also announced its attendance at the 43
rd
Annual J.P. Morgan Healthcare Conference in San Francisco commencing on January 13, 2025.
“At Dyadic, we remain committed to leveraging our innovative C1 and Dapibus™ protein production platforms to address some of the most pressing challenges in human health, agriculture, and biotechnology,” said Mark Emalfarb, Dyadic’s Chief Executive Officer, “Throughout 2024 our primary focus was on the production and monetization of alternative proteins which has provided a significant and sustainable near-term revenue opportunity for Dyadic. We will maintain that focus through 2025 as our partners prepare for multiple product launches in the Alternative Proteins business. Additionally, over the past several months we have experienced renewed industry interest in leveraging our C1 platform in human and animal health vaccines, and diagnostics. This is highlighted by our recently awarded $3 million grant from the Bill & Melinda Gates Foundation, focused on RSV and Malaria; our collaborations with ViroVax LLC (“ViroVax”) focused on the treatment of monkeypox (“Mpox”) and the diagnosis and treatment of human and avian influenza; and multiple partnerships with innovators seeking to produce infectious diseases antigens in the C1 platform. As we prepare for key product launches and engage with global partners, we are excited about the potential to deliver impactful solutions that address global health.”
Alternative Proteins
Cell Culture Media
Human Serum
Albumin:
In partnership with Proliant Health and Biologicals, Dyadic is progressing toward the launch in the first half of 2025 of Human Serum Albumin, a vital cell culture media component that supports cell growth, survival, and function. Additionally, we anticipate achieving a third milestone relating to a productivity threshold (totaling $500,000) during the first half of 2025.
Transferrin:
Recombinant transferrin offers a consistent, animal-free alternative to serum-derived transferrin, reducing variability and contamination risks in pharmaceutical cell culture media. Dyadic is currently in discussions with prospective partners, and providing samples for its recombinant transferrin products, in addition to further analytical and application testing.
Non-Animal Dairy Proteins
Dairy Enzymes:
A recombinant dairy enzyme for cheese production, produced using Dyadic’s Dapibus™ platform, is in the final stages of launch preparation and is expected to debut in 2025. Additional dairy enzymes are under development.
Alpha-Lactalbumin
: Sampling with interested food and reagent companies is underway. Dyadic continues to enhance its alpha-lactalbumin production and evaluate launch strategies for the reagent market.
Reagent Proteins
DNA-RNA Enzyme Products:
C1-produced DNase 1 (RNase-Free) enzyme
offering high purity and scalability for molecular diagnostics, biopharma, and other industries.
Additionally, Dyadic has developed stable prototypes of four additional DNA/RNA manipulation products including RNase Inhibitors and T7 RNA Polymerase for use in the biopharmaceutical industry.
Animal and Human Health
Through two collaborations with ViroVax, a C1-cell-produced self-assembling ferritin nanoparticle H5-2.3.4.4b A/Astrakhan bird flu antigen is being developed for use in diagnostic testing and vaccine applications targeting poultry, cattle, humans, and potentially companion animals, to help address the ongoing Bird Flu outbreak. Additionally, a C1-produced ferritin nanoparticle Mpox (monkeypox) vaccine continues to advance in early stages of development.
Diagnostic and Vaccine Advancement
:
The C1 produced adjuvanted self-assembling ferritin nanoparticle H5-2.3.4.4b A/Astrakhan H5 Avian Influenza vaccine candidate has demonstrated cross-protection against multiple H5 virus strains in studies conducted by ViroVax.
In Q4 2024, ViroVax commenced preclinical studies of the C1-produced ferritin nanoparticle Mpox (monkeypox) antigen.
Poultry Diagnostics and Vaccines
: Early studies using the C1-produced H5 antigen have generated neutralizing antibodies in poultry sera, highlighting its potential for diagnostics and disease prevention.
Cattle Diagnostics and Vaccines
: Initial results from cattle sera when using the C1-produced H5 antigen suggest cross-protection and promising diagnostic applications, further expanding the antigen’s utility.
J.P. Morgan Healthcare Conference
Dyadic management will attend the J.P. Morgan Healthcare Conference in San Francisco, January 13–16, 2025.
If you would like to schedule a meeting, please contact Dyadic at
assistant@dyadic.com
.
About Dyadic International, Inc.
Dyadic International, Inc., is a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness.
Dyadic’s microbial gene expression and protein production platforms are based on the highly productive and scalable fungus
Thermothelomyces heterothallica
(formerly
Myceliophthora thermophila
). Our lead platform, the C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and potentially improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
Dyadic is focusing on leveraging its microbial platform technologies for itself and its collaborators in a wide range of applications, including human and animal vaccines, therapeutics, food, nutrition, wellness, and internal biological products.
For more information about Dyadic International, visit
www.dyadic.com
.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at
www.dyadic.com
.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email:
ir@dyadic.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
